Gaucher Disease (GBA), 8 Variants

0051438
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive Mild Pathogenic
Positive Pathogenic

Icon

Additional Technical Information
Ordering Recommendation

Carrier screening or diagnostic testing for Gaucher disease for individuals of Ashkenazi Jewish descent.

Mnemonic
GBA
Methodology

Polymerase Chain Reaction/Fluorescence Monitoring

Performed

Tue, Fri

Reported

5-10 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or serum. Specimens collected in sodium heparin or lithium heparin tubes.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval

By report

Interpretive Data

Background information for Gaucher Disease (GBA), 8 Variants:
Characteristics: Gaucher disease affects lysosomal storage and has extreme symptom variability, ranging from perinatal lethality to asymptomatic individuals. Three Gaucher subtypes have been identified based on symptom characteristics. Type 1 is characterized by bone disease, hepatosplenomegaly, anemia, thrombocytopenia, and lung disease. Individuals with Type 1 disease do not have primary central nervous system (CNS) involvement. Type 2 is characterized by CNS symptoms displaying before age 2, which progresses rapidly resulting in death by age 4. In Type 3 disease, individuals may present as early as age 2 with display CNS symptoms. However, Type 3 disease progresses slowly, usually resulting in death during the third or fourth decade of life.
Incidence: 1 in 900 in Ashkenazi Jewish individuals.
Inheritance: Autosomal recessive.
Cause: GBA pathogenic variants.
Variants Tested: c.115+1G>A, p.L29Afs (c.84dupG), p.N409S (c.1226A>G), c.1263_1317del55, p.V433L (c.1297G>T), p.D448H (c.1342G>C), p.L483P (c.1448T>C), and p.R535H (c.1604G>A).
Clinical Sensitivity: 90 percent in Ashkenazi Jewish individuals; 55 percent in other ethnicities.
Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring.
Analytical Sensitivity and Specificity: Greater than 99 percent.
Limitations: Variants other than those tested will not be detected. Diagnostic errors can occur due to rare sequence variations.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
Hotline History
N/A
CPT Codes

81251

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
0051440 Gaucher Disease (GBA), Allele 1 46988-2
0051441 Gaucher Disease (GBA), Allele 2 46988-2
0051442 Gaucher Disease (GBA), Interpretation 35693-1
2001312 Gaucher Disease (GBA), Specimen 31208-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Beta-glucocerebrosidase deficiency
  • Beta-Glucosidase
  • Gaucher Disease
Gaucher Disease (GBA), 8 Variants